Global Premature Labor (Tocolysis) - Pipeline Review: H1 2020 -

DUBLIN--()--The "Premature Labor (Tocolysis) - Pipeline Review, H1 2020" drug pipelines has been added to's offering.

This report provides an overview of the Premature Labor (Tocolysis) (Women's Health) pipeline landscape.

Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Premature Labor (Tocolysis) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Labor (Tocolysis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Premature Labor (Tocolysis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Premature Labor (Tocolysis) (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Premature Labor (Tocolysis) - Overview
  • Premature Labor (Tocolysis) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Premature Labor (Tocolysis) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
  • Dare Bioscience Inc
  • GlaxoSmithKline Plc
  • ILIAS Biologics Inc
  • Lipocine Inc
  • ObsEva SA
  • Premature Labor (Tocolysis) - Drug Profiles
  • Premature Labor (Tocolysis) - Dormant Projects
  • Premature Labor (Tocolysis) - Discontinued Products
  • Premature Labor (Tocolysis) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 15, 2020: ObsEva to provide update on OBE022 at JP Morgan Healthcare Conference in San Francisco
  • Oct 10, 2019: Dar Bioscience announces a poster presentation on a pharmacokinetic study of DARE-FRT1, in development for sustained-release progesterone therapy for pregnancy maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo
  • Jul 26, 2019: ObsEva reports positive feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022
  • Mar 13, 2019: ObsEva to present OBE022 clinical data for treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
  • Jan 22, 2019: ObsEva SA reports initial good safety of OBE022 in pregnant women with preterm labour and announces start of part B of the PROLONG trial
  • Oct 30, 2018: Dare Bioscience to present preclinical data of DARE-FRT1 at AAPS 2018 meeting
  • Mar 01, 2018: ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting
  • Dec 05, 2017: ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
  • Sep 11, 2017: ObsEva Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting
  • Jun 29, 2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting
  • Jun 26, 2017: Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
  • May 18, 2017: ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022
  • Mar 17, 2017: ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
  • Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
  • Jan 09, 2017: Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
  • Appendix

Companies Mentioned

  • Dare Bioscience Inc
  • GlaxoSmithKline Plc
  • ILIAS Biologics Inc
  • Lipocine Inc
  • ObsEva SA

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900